Kura Oncology Inc.

(NASDAQ:KURA) Trade

By |

Equities News

Company chart and information is provided by TradingView based on 15-minute-delayed data.


Profile

Kura Oncology Inc is a clinical-stage biopharmaceutical company, engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signalling pathways to drive the progression of various cancers. The company has lead product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase (ERK), as a treatment for patients with pancreatic cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and melanoma. Geographically operation of the group is carried through the United States.

Contact Information

Website: www.kuraoncology.com
Email: pete@kuraoncology.com
Main Phone: +1 858 500-8800
Address: 3033 Science Park Road
Address 2: Suite 220
State: CA
City / Town: San Diego
Country: US
Postal Code: 92121

Issuer Information

Exchange: NGS
CEO: Troy E. Wilson
Employees: 89
NAICS: Biological Product (except Diagnostic) Manufacturing(325414)

Equities News

(%)
Company data no longer available
Last Price N/A Change $ N/A Change % N/A Tick N/A
Bid N/A Bid Size N/A Ask N/A Ask Size N/A
Open N/A High N/A Low N/A Prev Close N/A
Last Trade Volume N/A 52 Wk Hi N/A 52 Wk Low N/A
Market Cap N/A Ex-Div Date N/A Div Rate N/A Yield N/A
Shares N/A EPS (TTM) N/A PE Ratio N/A Exchange N/A